Trial Profile

Safety and pharmacokinetics study of adalimumab with Halozyme's proprietary ENHANZE technology

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Dec 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary) ; Hyaluronidase
Indications Immunological disorders
Focus Adverse reactions; Pharmacokinetics
Sponsors AbbVie

Most Recent Events

21 Nov 2016 According to a Halozyme Therapeutics, Inc media release, AbbVie has discontinued a development program using the Halozyme ENHANZE™ platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of this study in which the target results were not achieved.
21 Nov 2016 Status changed from recruiting to completed, as per a Halozyme Therapeutics media release.
25 Jan 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com